Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania gives an overview of what she learned from the phase III trial, Checkpoint 459, on the use of nivolumab in advanced HCC. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Phase 3 Checkpoint 459 Trial: Nivolumab in advanced HCC
